Assets
(6 total)
6Total Assets
2Approved
2Phase 3 / Filed
2Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Ivabradine(Corlanor) | Approved | If (funny) channelSmall molecule | Heart Failure |
Ivosidenib(Tibsovo) | Approved | Mutant IDH1Small molecule | Acute Myeloid Leukemia |
| Phase 3 | Protein kinase C (PKC) (inhibitor)Small molecule | Uveal Melanoma | |
Teneligliptin(Tenelia) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
| Phase 1/2 | KCNT1 mRNARNA / oligonucleotide | Epilepsy | |
| Phase 1/2 | RAFSmall molecule | Non-Small Cell Lung CancerAcute Myeloid Leukemia |
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (8)
January 2027 (2)
Est. primary completion 2027-01-15 · NCT05987332 · CT.gov ↗
What to watch
DarovasertibPhase 1/2Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Est. primary completion 2027-01-29 · NCT03947385 · CT.gov ↗
What to watch
April 2027 (1)
Est. primary completion 2027-04-30 · NCT05907954 · CT.gov ↗
What to watch
September 2027 (1)
Ivosidenib · TibsovoPhase 1/2Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Est. primary completion 2027-09-13 · NCT06501625 · CT.gov ↗
What to watch
October 2027 (1)
Est. primary completion 2027-10-15 · NCT05907057 · CT.gov ↗
What to watch
November 2027 (2)
S241656Phase 1/2Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia
Est. primary completion 2027-11-01 · NCT07719348 · CT.gov ↗
What to watch
Ivosidenib · TibsovoPhase 3Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Est. primary completion 2027-11-01 · NCT06465953 · CT.gov ↗
What to watch
December 2027 (1)
Est. primary completion 2027-12-01 · NCT05876754 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Ivosidenib · TibsovoPhase 3Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation …
Est. primary completion 2028-02-01 · NCT06127407 · CT.gov ↗
What to watch
April 2028 (1)
2030 (1)
October 2030 (1)
Est. primary completion 2030-10 · NCT07015190 · CT.gov ↗
What to watch
2034 (1)
March 2034 (1)
Est. primary completion 2034-03 · NCT07804186 · CT.gov ↗
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
13 April 2026Topline resultDarovasertibOptimUM-02 Phase 2/3 (NCT05987332) met its primary endpoint: PFS by BICR
IDEAYA Biosciences · Source ↗
Financial reports
No financial reports recorded.